306 related articles for article (PubMed ID: 22410801)
1. HER2 expression and its clinicopathological features in resectable gastric cancer.
Kataoka Y; Okabe H; Yoshizawa A; Minamiguchi S; Yoshimura K; Haga H; Sakai Y
Gastric Cancer; 2013 Jan; 16(1):84-93. PubMed ID: 22410801
[TBL] [Abstract][Full Text] [Related]
2. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).
Matsusaka S; Nashimoto A; Nishikawa K; Miki A; Miwa H; Yamaguchi K; Yoshikawa T; Ochiai A; Morita S; Sano T; Kodera Y; Kakeji Y; Sakamoto J; Saji S; Yoshida K
Gastric Cancer; 2016 Jul; 19(3):839-51. PubMed ID: 26265390
[TBL] [Abstract][Full Text] [Related]
4. Low frequency of HER2 amplification and overexpression in early onset gastric cancer.
Moelans CB; Milne AN; Morsink FH; Offerhaus GJ; van Diest PJ
Cell Oncol (Dordr); 2011 Apr; 34(2):89-95. PubMed ID: 21394646
[TBL] [Abstract][Full Text] [Related]
5. Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites.
Gumusay O; Benekli M; Ekinci O; Baykara M; Ozet A; Coskun U; Demirci U; Uner A; Dursun A; Atak EY; Buyukberber S
Jpn J Clin Oncol; 2015 May; 45(5):416-21. PubMed ID: 25732909
[TBL] [Abstract][Full Text] [Related]
6. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma.
Yoshida H; Yamamoto N; Taniguchi H; Oda I; Katai H; Kushima R; Tsuda H
Virchows Arch; 2014 Aug; 465(2):145-54. PubMed ID: 24889042
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
Park YS; Hwang HS; Park HJ; Ryu MH; Chang HM; Yook JH; Kim BS; Jang SJ; Kang YK
Hum Pathol; 2012 Mar; 43(3):413-22. PubMed ID: 21855114
[TBL] [Abstract][Full Text] [Related]
8. A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity.
Nishida Y; Kuwata T; Nitta H; Dennis E; Aizawa M; Kinoshita T; Ohtsu A; Ochiai A
Gastric Cancer; 2015 Jul; 18(3):458-66. PubMed ID: 24917219
[TBL] [Abstract][Full Text] [Related]
9. Relationship between HER2 expression and tumor interstitial angiogenesis in primary gastric cancer and its effect on prognosis.
Li F; Meng G; Tan B; Chen Z; Ji Q; Wang X; Liu C; Niu S; Li Y; Liu Y
Pathol Res Pract; 2021 Jan; 217():153280. PubMed ID: 33253925
[TBL] [Abstract][Full Text] [Related]
10. Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology.
Tsapralis D; Panayiotides I; Peros G; Liakakos T; Karamitopoulou E
World J Gastroenterol; 2012 Jan; 18(2):150-5. PubMed ID: 22253521
[TBL] [Abstract][Full Text] [Related]
11. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
[TBL] [Abstract][Full Text] [Related]
12. Correlation of HER2 expression with clinicopathological characteristics and prognosis in resectable gastric cancer.
Otsu H; Oki E; Ikawa-Yoshida A; Kawano H; Ando K; Ida S; Kimura Y; Aishima S; Saeki H; Morita M; Kohnoe S; Oda Y; Maehara Y
Anticancer Res; 2015 Apr; 35(4):2441-6. PubMed ID: 25862912
[TBL] [Abstract][Full Text] [Related]
13. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.
Van Cutsem E; Bang YJ; Feng-Yi F; Xu JM; Lee KW; Jiao SC; Chong JL; López-Sanchez RI; Price T; Gladkov O; Stoss O; Hill J; Ng V; Lehle M; Thomas M; Kiermaier A; Rüschoff J
Gastric Cancer; 2015 Jul; 18(3):476-84. PubMed ID: 25038874
[TBL] [Abstract][Full Text] [Related]
14. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer.
Sukawa Y; Yamamoto H; Nosho K; Kunimoto H; Suzuki H; Adachi Y; Nakazawa M; Nobuoka T; Kawayama M; Mikami M; Matsuno T; Hasegawa T; Hirata K; Imai K; Shinomura Y
World J Gastroenterol; 2012 Dec; 18(45):6577-86. PubMed ID: 23236232
[TBL] [Abstract][Full Text] [Related]
15. Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer.
Shun CT; Wu MS; Lin JT; Chen SY; Wang HP; Lee WJ; Wang TH; Chuang SM
Hepatogastroenterology; 1997; 44(14):604-9. PubMed ID: 9164544
[TBL] [Abstract][Full Text] [Related]
16. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
[TBL] [Abstract][Full Text] [Related]
17. [Her2 testing in gastric cancer. What is different in comparison to breast cancer?].
Rüschoff J; Nagelmeier I; Baretton G; Dietel M; Höfler H; Schildhaus HU; Büttner R; Schlake W; Stoss O; Kreipe HH
Pathologe; 2010 May; 31(3):208-17. PubMed ID: 20443098
[TBL] [Abstract][Full Text] [Related]
18. Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers.
Baykara M; Benekli M; Ekinci O; Irkkan SC; Karaca H; Demirci U; Akinci MB; Unal OU; Dane F; Turkoz FP; Balakan O; Eser EP; Ozturk SC; Ozkan M; Oksuzoglu B; Sevinc A; Demir N; Harputluoglu H; Yalcin B; Coskun U; Uner A; Ozet A; Buyukberber S;
J Gastrointest Surg; 2015 Sep; 19(9):1565-71. PubMed ID: 26179664
[TBL] [Abstract][Full Text] [Related]
19. Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization.
Kanayama K; Imai H; Yoneda M; Hirokawa YS; Shiraishi T
Cancer Sci; 2016 Apr; 107(4):536-42. PubMed ID: 26752196
[TBL] [Abstract][Full Text] [Related]
20. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.
Terashima M; Kitada K; Ochiai A; Ichikawa W; Kurahashi I; Sakuramoto S; Katai H; Sano T; Imamura H; Sasako M;
Clin Cancer Res; 2012 Nov; 18(21):5992-6000. PubMed ID: 22977193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]